22nd Annual · April 2024 · Virtual

2024

24 faculty
2 recordings

Symposium

Friday, April 19, 2024

Full recording 403 min

9:30 am
Introductory Notes on the 22nd Annual MCI Symposium
Ranjan Duara, MD, FAANMt Sinai Medical Center/Wien Center for Alzheimer's Disease and Memory Disorders, USA

9:30

Session 1

Role of Plasma Biomarkers of AD Pathology in Diagnosis of Patients with Cognitive Complaints

Chair: Steven DeKosky, MDUniversity of Florida, USA

9:30
Session Overview
9:40
Keynote Cognitive changes associated with Abeta and tau pathology in normal aging
Reisa Sperling, MDBrigham and Women’s Hospital, USA
10:15
Longitudinal changes in plasma biomarkers in ATRI studies, including the A4 Study
Robert Rissman, PhDUniversity of Southern California, USA
10:35
Plasma brain-derived tau as a sensitive biomarker of neurodegeneration
Thomas Karikari, PhDUniversity of Pittsburgh, USA
10:55
Relations of plasma biomarkers to imaging biomarkers in ethnically diverse individuals
Breton Asken, PhDUniversity of Florida, USA
11:15
Plasma biomarkers in Mild Behavioral Impairment
Firoza Lussier, MScUniversity of Pittsburgh, USA
11:35
Discussion
11:55
Break

12:25

Session 2

Implementation of a Treatment Program using Anti-Amyloid Monoclonal Antibodies

Chair: Ronald Petersen, MD, PhDMayo Clinic, Rochester, USA

12:25
Session Overview
12:30
Keynote Challenges in initiating anti-amyloid monoclonal antibody treatment
Suzanne Schindler, MD, PhDWashington University in St Louis, USA
1:10
Plasma biomarkers in the MCI population
Nicholas Ashton, PhDUniversity of Gothenburg, Sweden
1:30
Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease
Madhav Thambisetty, MD, PhDNIA, NIH, USA
1:50
Distinguishing subjective memory complaints from MCI and mild dementia in a multi-ethnic population
Rosie Curiel Cid, PsyDUniversity of Miami, USA
2:10
Plasma biomarker strategy for selecting patients for anti-amyloid immunotherapies and determining treatment response
Niklas Mattsson-Carlgren, MD, PhDLund University, Sweden
2:30
Break
2:45
Case Presentations: Determination of Candidacy for Anti Amyloid Treatment, AD, Risk for ARIA and Monitoring Treatment Progress
2:45
Appropriate use recommendation for anti-amyloid treatment for Alzheimer's disease
Gil Rabinovici, MDUCSF, USA
3:05
Evolution and management of ARIAs
Stephen Salloway, MD, MSBrown University, USA
3:25
Candidacy for anti-amyloid treatment
Vijay Ramanan, MD, PhDMayo Clinic, USA
3:45
Amyloid antibody treatment- presenting risk information to patients
Lawrence Honig, MD, PhDColumbia University, USA
4:05
Management of severe ARIA in patients treated with anti-amyloid therapy
John Dickson, MD, PhDMassachusetts General Hospital, USA
4:25
Group Discussion
4:50
Conclusion
Ranjan Duara, MD, FAANMount Sinai Medical Center Miami, USA
5:00
Symposium ends

Public Forum

Friday, April 26, 2024

Full recording 177 min

10:00 am
Welcome and Introductions
Ranjan Duara, MD, FAANMount Sinai Medical Center
10:05
Experiences of a Caregiver
David LawrenceRetired Publisher of The Miami Herald, and Chair of The Children’s Movement of Florida
10:25
Normal Aging, MCI, Dementia and Cognitive Reserve – What Are They and How Do We Assess Them?
Rosie Curiel Cid, PsyDUniversity of Miami
10:45
Amyloid, Tau and All That Jazz
Todd Golde, PhDEmory University
11:05
Translating Advances in Alzheimer’s Disease Research into “Real World” Clinical Care
Gil Rabinovici, MDUCSF
11:25
Blood-based Biomarkers and Free-Water Imaging in AD
Jesse DeSimone, PhDUniversity of Florida, Gainesville
11:45
The New Era of Anti-Amyloid Treatments for AD
Marc Agronin, MDMiami Jewish Health
12:05
The Challenges of Undergoing Anti-Amyloid Treatment - Patient/Caregiver Perspective
Clayton JonesThe Clay and Debbie Jones Family Foundation
12:25
What Alternatives Do We Have for Pharmacological Treatment of AD?
Marla Berg-Weger, PhDSt Louis University
12:45
Discussion: Faculty and Public Concluding Remarks
Moderator: Ranjan Duara, MD, FAAN
1:00 pm
End

Programs, recordings and slides as published at the time. Slides and recordings appear only where speakers chose to share them. Affiliations are as of 2024.